Literature DB >> 28627174

Integrative Analysis of Renal Ischemia/Reperfusion Injury and Remote Ischemic Preconditioning in Mice.

Kumsun Cho1,2, Sang-Il Min1,3, Sanghyun Ahn3, Seung-Kee Min3, Curie Ahn4, Kyung-Sang Yu1,2, In-Jin Jang1,2, Joo-Youn Cho1,2, Jongwon Ha1,3.   

Abstract

Remote ischemic preconditioning (RIPC) is a strategy to induce resistance in a target organ against the oxidative stress and injury caused by ischemia and reperfusion (IR). RIPC harnesses the body's endogenous protective capabilities through brief episodes of IR applied in organs remote from the target. Few studies have analyzed this phenomenon in the kidney. Furthermore, the window of protection representing RIPC efficacy has not been fully elucidated. Here, we performed a multiomics study to specify those associated with protective effects of RIPC against the IR injury. A total of 30 mice were divided to four groups: sham, IR only, late RIPC + IR, and early RIPC + IR. We found that IR clearly led to tubular injury, whereas both preconditioning groups exhibited attenuated injury after the insult. In addition, renal IR injury produced changes of the metabolome in kidney, serum, and urine specimens. Furthermore, distinctive mRNA and associated protein expression changes supported potential mechanisms. Our findings revealed that RIPC effectively reduces renal damage after IR and that the potential mechanisms differed between the two time windows of protection. These results may potentially be extended to humans to allow non- or minimally invasive diagnosis of renal IR injury and RIPC efficacy.

Entities:  

Keywords:  ischemia; kidney; multiomics; remote ischemic preconditioning; reperfusion

Mesh:

Year:  2017        PMID: 28627174     DOI: 10.1021/acs.jproteome.7b00167

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  7 in total

Review 1.  The role of dihydrosphingolipids in disease.

Authors:  Ruth R Magaye; Feby Savira; Yue Hua; Darren J Kelly; Christopher Reid; Bernard Flynn; Danny Liew; Bing H Wang
Journal:  Cell Mol Life Sci       Date:  2018-12-06       Impact factor: 9.261

Review 2.  Preclinical models versus clinical renal ischemia reperfusion injury: A systematic review based on metabolic signatures.

Authors:  Lente J S Lerink; Michèle J C de Kok; John F Mulvey; Sylvia E Le Dévédec; Alexander A Markovski; Rob C I Wüst; Ian P J Alwayn; Rutger J Ploeg; Alexander F M Schaapherder; Jaap A Bakker; Jan H N Lindeman
Journal:  Am J Transplant       Date:  2021-11-01       Impact factor: 9.369

3.  Early detection of unilateral ureteral obstruction by desorption electrospray ionization mass spectrometry.

Authors:  Shibdas Banerjee; Anny Chuu-Yun Wong; Xin Yan; Bo Wu; Hongjuan Zhao; Robert J Tibshirani; Richard N Zare; James D Brooks
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

4.  Remote Ischemic Preconditioning Ameliorates Renal Fibrosis After Ischemia-Reperfusion Injury via Transforming Growth Factor beta1 (TGF-β1) Signalling Pathway in Rats.

Authors:  Changcheng Zhou; Jingyu Liu; Yuzheng Ge; Yunpeng Zhu; Liuhua Zhou; Luwei Xu; Zheng Xu; Ran Wu; Ruipeng Jia
Journal:  Med Sci Monit       Date:  2020-02-06

5.  Evaluating the effect of remote ischemic preconditioning on kidney ischemia-reperfusion injury.

Authors:  Mahsan Samadi; Farinaz Tabibian; Kobra Moradzadeh; Seyed Mahdi Nassiri; Yousof Gheisari
Journal:  J Res Med Sci       Date:  2020-01-20       Impact factor: 1.852

6.  Rapid Identification of Ischemic Injury in Renal Tissue by Mass-Spectrometry Imaging.

Authors:  T C van Smaalen; S R Ellis; N E Mascini; T Porta Siegel; B Cillero-Pastor; L M Hillen; L W E van Heurn; C J Peutz-Kootstra; R M A Heeren
Journal:  Anal Chem       Date:  2019-02-15       Impact factor: 6.986

7.  Remote Ischemic Preconditioning Protects Cisplatin-Induced Acute Kidney Injury through the PTEN/AKT Signaling Pathway.

Authors:  Wanfen Zhang; Cheng Chen; Ran Jing; Tongqiang Liu; Bicheng Liu
Journal:  Oxid Med Cell Longev       Date:  2019-11-03       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.